Literature DB >> 31212398

Chemoprevention:zzm321990A new concept for cancerzzm321990prevention in primary care

Jon Emery1, Peter Nguyen2, Jesse Minshall3, Kara-Lynne Cummings4, Jennifer Walker5.   

Abstract

Background: Prevention of cancer in primary care has focused on modifying behaviours associated with increased risk of cancer (primary prevention) or increasing participation in national cancer screening programs (secondary prevention). On the basis of metaanalyses of large prevention trials, a new paradigm in primary prevention – chemoprevention – is beginning to enter the realms of primary care for specific populations.
Objectives: In this article, we discuss two examples of cancer chemoprevention relevant to general practice: low-dose aspirin for the prevention of colorectal cancer in people aged 50–70 years, and selective oestrogen receptor modulators (SERMs) for women at increased risk of breast cancer. We present new expected frequency trees that show the absolute benefits and harms of taking these medications in specific populations. Discussion: These expected frequency trees can serve as risk-communication aids to support shared decision making and the implementation of new chemoprevention guidelines in general practice.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 31212398     DOI: 10.31128/AJGP-07-18-4644

Source DB:  PubMed          Journal:  Aust J Gen Pract


  2 in total

1.  Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Authors:  Peter Nguyen; Jennifer McIntosh; Adrian Bickerstaffe; Sanjaya Maddumarachchi; Kara-Lynne Cummings; Jon D Emery
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

2.  Study on the Effect of Positive Psychological Intervention Based on PERMA Model on Perioperative Patients with AIDS Complicated with Breast Cancer.

Authors:  Lingmei Luo; Ying Li; Zhou Zhou; Saifen Yang; Yao Qin; Hua Peng; Yirong Wang; Zhe Li; Tianqin Yin
Journal:  Comput Math Methods Med       Date:  2022-08-08       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.